Related references
Note: Only part of the references are listed.Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Identification of an Immunogenic CTL Epitope of HIFPH3 for Immunotherapy of Renal Cell Carcinoma
Eiji Sato et al.
CLINICAL CANCER RESEARCH (2008)
Autoantibodies to tumor-associated antigens: reporters from the immune system
Eng M. Tan et al.
IMMUNOLOGICAL REVIEWS (2008)
The role of hypoxia-inducible factors in cancer
M. A. Maynard et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2007)
Expression of livin in renal cell carcinoma and detection of anti-livin autoantibody in patients
Hiroshi Kitamura et al.
UROLOGY (2007)
Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer
Animesh Barua et al.
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2007)
Antiprostasome antibodies:: Possible serum markers for prostate cancer metastasizing liability
Anders Larsson et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2006)
Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor
RJ Appelhoff et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Clinical usefulness of serum antip53 antibodies for prostate cancer detection: A comparative study with prostate specific antigen parameters
H Suzuki et al.
JOURNAL OF UROLOGY (2004)
Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor
M Hirsilä et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Detection of anti-livin antibody in gastrointestinal cancer patients
A Yagihashi et al.
CLINICAL CHEMISTRY (2003)
Differential regulation of HIF-1α prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells
CL Cioffi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma
H Shimada et al.
SURGERY (2002)
Share Paper
